Early risk factors for pregnancy loss in lupus

Obstetrics and Gynecology

Volumn 107, Issue 2, 2006, Pages 293-299

  Clowse, Megan E B ^a   Magder, Laurence S ^b   Witter, Frank ^b   Petri, Michelle ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; PREGNANCY; RISK FACTOR; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTIPHOSPHOLIPID SYNDROME; BLOOD PRESSURE; COHORT ANALYSIS; HIGH RISK PREGNANCY; HYPERTENSION; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; PATIENT MONITORING; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; STILLBIRTH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

ABORTION, SPONTANEOUS; ADULT; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK FACTORS;

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HEPARIN;

EID: 33645453962     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000194205.95870.86     Document Type: Article

References (33)

1. Petri M, Allbritton J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. J Rheumatol 1993;20:650-6.
2. Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001;10:91-6.
3. Clowse M, Witter FR, Magder LC, Petri M. The impact of increased lupus activity on obstetrical outcomes. Arthritis Rheum 2005;52:514-21.
4. Scott JR. Risks to the children born to mothers with autoimmune diseases. Lupus 2002;11:655-60.
5. Georgiou PE, Politi EN, Katsimbri P, Sakka V, Drosos AA. Outcome of lupus pregnancy: a controlled study. Rheumatology (Oxford) 2000;39:1014-9.
6. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002;41:643-50.
7. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol 2003;16:161-7.
8. Bobrie G, Liote F, Houillier P, Grunfeld JP, Jungers P. Pregnancy in lupus nephritis and related disorders. Am J Kidney Dis 1987;9:339-43.
9. Lockshin MD. Antiphospholipid antibody and antiphospholipid antibody syndrome. Curr Opin Rheumatol 1991;3:797-802.
10. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983;287:1088-9.
11. Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001;10:457-60.
12. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
13. Christopher-Stine L, Petri M, Astor BC, Fine D. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol 2004;31:1557-9.
14. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301-4.
15. Van Horn JT, Craven C, Ward K, Branch DW, Silver RM. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004;25:642-8.
16. Levy RA, Avvad E, Oliveira J, Porto LC. Placental pathology in antiphospholipid syndrome. Lupus 1998;7( Suppl 2):S81-5.
17. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002;61(Suppl 2):ii 46-50.
18. Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002;99:135-44.
19. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004;26:729-34.
20. Pauzner R, Dulitzki M, Langevitz P, Livneh A, Kenett R, Many A. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost 2001;86:1379-84.
21. Hyer JS, Fong S, Kutteh WH. Predictive value of the presence of an embryonic heartbeat for live birth: comparison of women with and without recurrent pregnancy loss. Fertil Steril 2004;82:1369-73.
22. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-9.
23. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13.
24. Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003;30:2127-32.
25. Petri M. Hopkins Lupus Pregnancy Center: 1987 to 1996. Rheum Dis Clin North Am 1997;23:1-13.
26. Chakravarty EF, Colon I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005;192:1897-904.
27. Zetterstrom K, Lindeberg SN, Haglund B, Hanson U. Maternal complications in women with chronic hypertension: a population-based cohort study. Acta Obstet Gynecol Scand 2005;84:419-24.
28. Clowse M, Magder LC, Petri M. Complement and anti-dsDNA titers are predictive of pregnancy outcomes. Arthritis Rheum 2004;50:A1011.
29. Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus: identification of racial and socioeconomic influences. Arch Intern Med 1990;150:849-53.
30. Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002;11:161-7.
31. Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60.
32. Diri E, Cucurull E, Gharavi AE, Kapoor D, Mendez EA, Scopelitis E, et al. Antiphospholipid (Hughes’) syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 1999;8:263-8.
33. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am 1997;81:151-77.